Related Experiment Video
Updated: Mar 9, 2026
Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis
Published on: January 5, 2024
Schiff base-Poloxamer P85 combination demonstrates chemotherapeutic effect on prostate cancer cells in vitro
Selami Demirci1, Ayşegül Doğan2, Neşe Başak Türkmen3
1Department of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, Istanbul, Turkey; National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, United States.
Abstract:
Prostate cancer is a multistep and complicated cancer type that is regulated by androgens at the cellular level and remains the second commonest cause of death among men. Discovery and development of novel chemotherapeutic agents enabling rapid tumor cell death with minimal toxic effects to healthy tissues might greatly improve the safety of chemotherapy. The present study evaluates the anti-cancer activity of a novel heterodinuclear copper(II)Mn(II) complex (Schiff base) in combination with poly(ethylene oxide) and poly(propylene oxide) block copolymer (Pluronic) P85. We used assays for cell proliferation, apoptosis, cell migration and invasion, DNA binding and cleavage to elucidate the molecular mechanisms of action, in addition to the anti-inflammatory potency of the new combination. The combined treatment of Schiff base and P85 lead to a remarkable anti-cancer effect on prostate cancer cell lines. Cell proliferation was inhibited in Schiff base-P85 treatment. The activity of this formulation is on DNA binding and cleavage and prevents inflammation in in vitro conditions. This is the first study presenting the anti-cancer activity of the present Schiff base derivative and its combination with P85 to treat prostate cancer in vitro.
Insights
This study shows a new Schiff base and Pluronic P85 combination effectively inhibits prostate cancer cell growth. The formulation targets DNA and reduces inflammation, offering a promising new approach for cancer treatment.
Area of Science:
- Oncology
- Materials Science
- Biochemistry
Background:
- Prostate cancer is a leading cause of male mortality, driven by androgens.
- Developing safer chemotherapeutics with minimal side effects is crucial.
- Novel agents are needed to enhance tumor cell death and improve treatment safety.
Purpose of the Study:
- To evaluate the anti-cancer activity of a novel heterodinuclear copper(II)Mn(II) complex (Schiff base).
- To assess the synergistic effect of the Schiff base in combination with Pluronic P85.
- To elucidate the molecular mechanisms of action and anti-inflammatory potential of the combination therapy.
Main Methods:
- In vitro assays for cell proliferation, apoptosis, migration, and invasion.
- DNA binding and cleavage assays.
- Evaluation of anti-inflammatory effects.
Main Results:
- The Schiff base-Pluronic P85 combination demonstrated significant anti-cancer effects on prostate cancer cell lines.
- Inhibition of cell proliferation was observed with the combined treatment.
- The formulation exhibited activity in DNA binding and cleavage and reduced inflammation in vitro.
Conclusions:
- The novel Schiff base-Pluronic P85 combination shows potent in vitro anti-cancer activity against prostate cancer.
- The mechanism involves DNA interaction and anti-inflammatory effects.
- This represents the first study on this Schiff base derivative and its combination with P85 for prostate cancer treatment.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019